摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-{2-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethoxy}benzylidene)thiazolidine-2,4-dione

中文名称
——
中文别名
——
英文名称
5-(4-{2-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethoxy}benzylidene)thiazolidine-2,4-dione
英文别名
(5Z)-5-[[4-[[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione
5-(4-{2-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethoxy}benzylidene)thiazolidine-2,4-dione化学式
CAS
——
化学式
C32H28ClN7O3S
mdl
——
分子量
626.138
InChiKey
KUNYPHWAOORKAY-PKAZHMFMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    44
  • 可旋转键数:
    11
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    153
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(4-{2-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethoxy}benzylidene)thiazolidine-2,4-dione 在 potassium hydroxide 作用下, 以 乙酸乙酯 为溶剂, 以73%的产率得到5-(4-{2-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethoxy}benzylidene)thiazolidine-2,4-dione dipotassium salt
    参考文献:
    名称:
    Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor
    摘要:
    Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT(1)) receptor and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-gamma and to block AT(1) receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-gamma activating and AT(1) blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach. (C) 2018 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2018.08.082
  • 作为产物:
    参考文献:
    名称:
    Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor
    摘要:
    Because of the complex biological networks, many pathologic disorders fail to be treated with a molecule directed towards a single target. Thus, combination therapies are often necessary, but they have many drawbacks. An alternative consists in building molecules intended to interact with multiple targets, called designed multiple ligands. We followed such a strategy in order to treat metabolic syndrome, by setting up molecules directed towards both type 1 angiotensin II (AT(1)) receptor and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). For this purpose, many molecules were prepared by merging both pharmacophores following three different strategies. Their ability to activate PPAR-gamma and to block AT(1) receptors were evaluated in vitro. This strategy led to the preparation of many new PPAR-gamma activating and AT(1) blocking molecules. Among them, some exhibited both activities, highlighting the convenience of this approach. (C) 2018 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2018.08.082
点击查看最新优质反应信息